Ludvigsson Johnny
a Divsion of Pediatrics, Department of Clinical and Experimental Medicine , Linköping University , Linköping , Sweden.
Expert Opin Biol Ther. 2017 Aug;17(8):1033-1043. doi: 10.1080/14712598.2017.1328495. Epub 2017 May 25.
In spite of modern techniques, the burden for patients with type 1 diabetes (T1D) will not disappear and T1D remains a life-threatening disease causing severe complications and increased mortality. We have to learn how to preserve residual insulin secretion or even increase beta cell regeneration. This would give a milder disease, simpler treatment and perhaps even cure. Thus, there are good reasons to try therapies that may preserve beta cell function. Areas covered: In this review the author reviews the literature and registered ongoing trials using GAD-alum put in relation to the high number of published different immune interventions. Expert opinion: GAD-alum treatment is safe, tolerable and easy for the patients and healthcare. It seems probable that treatment with GAD65-alum 20 µg sc can preserve residual beta cell function in T1D, but efficacy needs to be improved. This may be achieved by the use of combination therapies and new approaches for administration.
尽管有现代技术，但1型糖尿病（T1D）患者的负担不会消失，T1D仍然是一种危及生命的疾病，会导致严重并发症并增加死亡率。我们必须学会如何保留残余的胰岛素分泌，甚至增加β细胞再生。这将使病情更轻、治疗更简单，甚至可能治愈。因此，有充分的理由尝试可能保留β细胞功能的疗法。涵盖领域：在本综述中，作者回顾了相关文献以及已注册的正在进行的使用GAD-明矾的试验，并将其与已发表的大量不同免疫干预措施联系起来。专家意见：GAD-明矾治疗对患者和医疗保健来说是安全、可耐受且简便的。用20μg皮下注射GAD65-明矾治疗似乎有可能保留T1D患者残余的β细胞功能，但疗效需要提高。这可以通过联合治疗和新的给药方法来实现。
